Cidara Therapeutics (CDTX) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart

CDTX Stock Forecast

Cidara Therapeutics stock forecast is as follows: an average price target of $12.00 (represents a -48.32% downside from CDTX’s last price of $23.22) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.

CDTX Price Target

The average price target for Cidara Therapeutics (CDTX) is $12.00 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $12.00 to $12.00. This represents a potential -48.32% downside from CDTX's last price of $23.22.

CDTX Analyst Ratings

Buy

According to 2 Wall Street analysts, Cidara Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for CDTX stock is 0 'Strong Buy' (0.00%), 2 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Cidara Therapeutics Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Aug 14, 2024	Ed Arce	H.C. Wainwright	$12.00	$6.43	86.63%	-48.32%

The latest Cidara Therapeutics stock forecast, released on Aug 14, 2024 by Ed Arce from H.C. Wainwright, set a price target of $12.00, which represents a 86.63% increase from the stock price at the time of the forecast ($6.43), and a -48.32% decrease from CDTX last price ($23.22).

Cidara Therapeutics Price Target by Period

	1M	3M	12M
# Anlaysts	-	-	1
Avg Price Target	-	-	$12.00
Last Closing Price	$23.22	$23.22	$23.22
Upside/Downside	-100.00%	-100.00%	-48.32%

In the current month, the average price target of Cidara Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Cidara Therapeutics's last price of $23.22. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Aug 14, 2024	H.C. Wainwright		Buy	Upgrade
May 12, 2022	Needham	Buy	Buy	Hold

Cidara Therapeutics's last stock rating was published by H.C. Wainwright on Aug 14, 2024. The company Upgrade its CDTX rating from "null" to "Buy".

Cidara Therapeutics Financial Forecast

Cidara Therapeutics Revenue Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
Revenue	-	-	-	-	-	-	-	-	-	$12.72M	$7.61M	$25.99M	$10.22M	$40.74M	$6.22M	$7.11M	$7.22M	$7.08M	$32.86M	$2.41M	$3.73M	$2.42M	$3.39M	$2.53M	$1.81M	$19.10M
Avg Forecast	-	-	-	-	$240.00K	$433.33K	$1.30M	$9.03M	$13.95M	$8.14M	$11.55M	$18.68M	$10.57M	$28.35M	$6.21M	$5.89M	$4.31M	$2.94M	$12.13M	$7.88M	$12.95M	$4.89M	$5.29M	$2.25M	$3.63M	$7.50M
High Forecast	-	-	-	-	$240.00K	$433.33K	$1.30M	$9.03M	$13.95M	$8.14M	$11.55M	$18.68M	$10.57M	$28.35M	$6.21M	$5.89M	$4.31M	$2.94M	$12.13M	$7.88M	$12.95M	$4.89M	$5.29M	$2.25M	$3.63M	$7.50M
Low Forecast	-	-	-	-	$240.00K	$433.33K	$1.30M	$9.03M	$13.95M	$8.14M	$11.55M	$18.68M	$10.57M	$28.35M	$6.21M	$5.89M	$4.31M	$2.94M	$12.13M	$7.88M	$12.95M	$4.89M	$5.29M	$2.25M	$3.63M	$7.50M
# Analysts	-	-	-	-	5	4	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
Surprise %	-	-	-	-	-	-	-	-	-	1.56%	0.66%	1.39%	0.97%	1.44%	1.00%	1.21%	1.68%	2.41%	2.71%	0.31%	0.29%	0.49%	0.64%	1.12%	0.50%	2.55%

Cidara Therapeutics's average Quarter revenue forecast for Dec 23 based on 2 analysts is $13.95M, with a low forecast of $13.95M, and a high forecast of $13.95M. CDTX's average Quarter revenue forecast represents a 9.69% increase compared to the company's last Quarter revenue of $12.72M (Sep 23).

Cidara Therapeutics EBITDA Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	-	-	-	-	5	4	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
EBITDA	-	-	-	-	-	-	-	-	-	$-8.55M	$-12.83M	$2.98M	$-13.27M	$15.23M	$-12.81M	$-17.96M	$-18.19M	$-17.99M	$10.82M	$-18.23M	$-21.57M	$-17.56M	$-18.23M	$-14.47M	$-13.95M	$3.12M
Avg Forecast	-	-	-	-	$-180.12K	$-325.22K	$-975.67K	$-16.79M	$-10.47M	$-6.11M	$-8.67M	$-17.95M	$-17.15M	$-20.95M	$-4.59M	$-19.20M	$-3.19M	$-2.17M	$-8.96M	$-10.03M	$-9.57M	$-3.61M	$-3.91M	$-9.36M	$-2.69M	$-5.54M
High Forecast	-	-	-	-	$-180.12K	$-325.22K	$-975.67K	$-13.43M	$-10.47M	$-6.11M	$-8.67M	$-14.36M	$-13.72M	$-20.95M	$-4.59M	$-15.36M	$-3.19M	$-2.17M	$-8.96M	$-8.02M	$-9.57M	$-3.61M	$-3.91M	$-7.49M	$-2.69M	$-5.54M
Low Forecast	-	-	-	-	$-180.12K	$-325.22K	$-975.67K	$-20.15M	$-10.47M	$-6.11M	$-8.67M	$-21.55M	$-20.58M	$-20.95M	$-4.59M	$-23.04M	$-3.19M	$-2.17M	$-8.96M	$-12.04M	$-9.57M	$-3.61M	$-3.91M	$-11.23M	$-2.69M	$-5.54M
Surprise %	-	-	-	-	-	-	-	-	-	1.40%	1.48%	-0.17%	0.77%	-0.73%	2.79%	0.94%	5.71%	8.27%	-1.21%	1.82%	2.25%	4.86%	4.67%	1.55%	5.19%	-0.56%

1 analysts predict CDTX's average Quarter EBITDA for Jun 23 to be $-8.67M, with a high of $-8.67M and a low of $-8.67M. This is -391.09% lower than Cidara Therapeutics's previous annual EBITDA (Mar 23) of $2.98M.

Cidara Therapeutics Net Income Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	-	-	-	-	5	4	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
Net Income	-	-	-	-	-	-	-	-	-	$-8.17M	$-12.36M	$3.21M	$-13.38M	$14.98M	$-13.13M	$-18.30M	$-16.84M	$-18.08M	$10.71M	$-18.29M	$-21.63M	$-17.63M	$-18.31M	$-14.54M	$-14.02M	$3.04M
Avg Forecast	$-9.83M	$-21.06M	$-27.26M	$-27.79M	$-22.82M	$-27.75M	$-26.77M	$-17.08M	$-9.80M	$-19.59M	$-16.98M	$-18.27M	$-17.21M	$-547.65K	$-25.56M	$-19.54M	$-29.66M	$-33.01M	$-19.78M	$-10.06M	$-21.91M	$-36.83M	$-25.64M	$-9.41M	$-39.47M	$-51.41M
High Forecast	$-9.83M	$-21.06M	$-27.26M	$-27.79M	$-22.82M	$-27.75M	$-26.77M	$-13.67M	$-9.80M	$-19.59M	$-16.98M	$-14.62M	$-13.76M	$-547.65K	$-25.56M	$-15.63M	$-29.66M	$-33.01M	$-19.78M	$-8.05M	$-21.91M	$-36.83M	$-25.64M	$-7.53M	$-39.47M	$-51.41M
Low Forecast	$-9.83M	$-21.06M	$-27.26M	$-27.79M	$-22.82M	$-27.75M	$-26.77M	$-20.50M	$-9.80M	$-19.59M	$-16.98M	$-21.93M	$-20.65M	$-547.65K	$-25.56M	$-23.45M	$-29.66M	$-33.01M	$-19.78M	$-12.07M	$-21.91M	$-36.83M	$-25.64M	$-11.29M	$-39.47M	$-51.41M
Surprise %	-	-	-	-	-	-	-	-	-	0.42%	0.73%	-0.18%	0.78%	-27.35%	0.51%	0.94%	0.57%	0.55%	-0.54%	1.82%	0.99%	0.48%	0.71%	1.55%	0.36%	-0.06%

Cidara Therapeutics's average Quarter net income forecast for Jun 23 is $-16.98M, with a range of $-16.98M to $-16.98M. CDTX's average Quarter net income forecast represents a -629.08% decrease compared to the company's last Quarter net income of $3.21M (Mar 23).

Cidara Therapeutics SG&A Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	-	-	-	-	5	4	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
SG&A	-	-	-	-	-	-	-	-	-	$3.56M	$3.31M	$4.30M	$3.43M	$5.78M	$4.07M	$5.20M	$4.98M	$4.61M	$4.37M	$4.78M	$4.15M	$3.69M	$3.97M	$4.09M	$4.41M	$4.57M
Avg Forecast	-	-	-	-	$146.23K	$264.02K	$792.07K	$4.86M	$8.50M	$4.96M	$7.03M	$5.20M	$3.30M	$17.27M	$3.78M	$5.56M	$2.63M	$1.79M	$7.39M	$2.63M	$7.89M	$2.98M	$3.22M	$1.37M	$2.21M	$4.57M
High Forecast	-	-	-	-	$146.23K	$264.02K	$792.07K	$5.84M	$8.50M	$4.96M	$7.03M	$6.24M	$3.96M	$17.27M	$3.78M	$6.68M	$2.63M	$1.79M	$7.39M	$3.16M	$7.89M	$2.98M	$3.22M	$1.37M	$2.21M	$4.57M
Low Forecast	-	-	-	-	$146.23K	$264.02K	$792.07K	$3.89M	$8.50M	$4.96M	$7.03M	$4.16M	$2.64M	$17.27M	$3.78M	$4.45M	$2.63M	$1.79M	$7.39M	$2.10M	$7.89M	$2.98M	$3.22M	$1.37M	$2.21M	$4.57M
Surprise %	-	-	-	-	-	-	-	-	-	0.72%	0.47%	0.83%	1.04%	0.33%	1.08%	0.94%	1.90%	2.57%	0.59%	1.82%	0.53%	1.24%	1.23%	2.99%	1.99%	1.00%

Cidara Therapeutics's average Quarter SG&A projection for Dec 23 is $8.50M, based on 2 Wall Street analysts, with a range of $8.50M to $8.50M. The forecast indicates a 139.02% rise compared to CDTX last annual SG&A of $3.56M (Sep 23).

Cidara Therapeutics EPS Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	-	-	-	-	5	4	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
EPS	-	-	-	-	-	-	-	-	-	$-0.09	$-0.14	$0.03	$-0.19	$0.17	$-0.19	$-0.27	$-0.26	$-0.37	$0.18	$-0.39	$-0.50	$-0.41	$-0.45	$-0.46	$-0.42	$0.08
Avg Forecast	$-1.50	$-3.23	$-4.17	$-4.25	$-3.50	$-4.25	$-4.10	$-2.39	$-1.50	$-3.00	$-2.60	$-0.73	$-2.93	$-0.12	$-5.60	$-5.56	$-6.50	$-7.23	$-4.33	$-6.70	$-4.80	$-8.07	$-5.62	$-6.80	$-8.65	$-11.27
High Forecast	$-1.50	$-3.23	$-4.17	$-4.25	$-3.50	$-4.25	$-4.10	$-2.39	$-1.50	$-3.00	$-2.60	$-0.73	$-2.93	$-0.12	$-5.60	$-5.56	$-6.50	$-7.23	$-4.33	$-6.70	$-4.80	$-8.07	$-5.62	$-6.80	$-8.65	$-11.27
Low Forecast	$-1.50	$-3.23	$-4.17	$-4.25	$-3.50	$-4.25	$-4.10	$-2.39	$-1.50	$-3.00	$-2.60	$-0.73	$-2.93	$-0.12	$-5.60	$-5.56	$-6.50	$-7.23	$-4.33	$-6.70	$-4.80	$-8.07	$-5.62	$-6.80	$-8.65	$-11.27
Surprise %	-	-	-	-	-	-	-	-	-	0.03%	0.05%	-0.04%	0.06%	-1.42%	0.03%	0.05%	0.04%	0.05%	-0.04%	0.06%	0.10%	0.05%	0.08%	0.07%	0.05%	-0.01%

According to 1 Wall Street analysts, Cidara Therapeutics's projected average Quarter EPS for Jun 23 is $-2.60, with a low estimate of $-2.60 and a high estimate of $-2.60. This represents a -8766.67% decrease compared to CDTX previous annual EPS of $0.03 (Mar 23).

Cidara Therapeutics Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
GLYC	GlycoMimetics	$0.23	$13.00	5552.17%
CTMX	CytomX Therapeutics	$1.13	$3.47	207.08%	Buy
CDTX	Cidara Therapeutics	$22.81	$12.00	-47.39%	Buy

CDTX Forecast FAQ

Is Cidara Therapeutics a good buy?

Yes, according to 2 Wall Street analysts, Cidara Therapeutics (CDTX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 100.00% of CDTX's total ratings.

What is CDTX's price target?

Cidara Therapeutics (CDTX) average price target is $12 with a range of $12 to $12, implying a -48.32% from its last price of $23.22. The data is based on 2 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Cidara Therapeutics stock go up soon?

According to Wall Street analysts' prediction for CDTX stock, the company can go down by -48.32% (from the last price of $23.22 to the average price target of $12), down by -48.32% based on the highest stock price target, and down by -48.32% based on the lowest stock price target.

Can Cidara Therapeutics stock reach $30?

CDTX's average twelve months analyst stock price target of $12 does not support the claim that Cidara Therapeutics can reach $30 in the near future.

What are Cidara Therapeutics's analysts' financial forecasts?

Cidara Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $11.01M (high $11.01M, low $11.01M), average EBITDA is $-18.269M (high $-14.911M, low $-21.626M), average net income is $-94.433M (high $-91.016M, low $-97.85M), average SG&A $6.07M (high $7.04M, low $5.09M), and average EPS is $-14.232 (high $-14.232, low $-14.232). CDTX's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-85.936M (high $-85.936M, low $-85.936M), average SG&A $0 (high $0, low $0), and average EPS is $-13.16 (high $-13.16, low $-13.16).

Did the CDTX's actual financial results beat the analysts' financial forecasts?

Based on Cidara Therapeutics's last annual report (Dec 2022), the company's revenue was $64.29M, beating the average analysts forecast of $51.01M by 26.03%. Apple's EBITDA was $-29.718M, missing the average prediction of $-61.897M by -51.99%. The company's net income was $-29.799M, missing the average estimation of $-62.853M by -52.59%. Apple's SG&A was $18.49M, missing the average forecast of $29.91M by -38.20%. Lastly, the company's EPS was $-0.43, missing the average prediction of $-14.213 by -96.97%. In terms of the last quarterly report (Sep 2023), Cidara Therapeutics's revenue was $12.72M, beating the average analysts' forecast of $8.14M by 56.25%. The company's EBITDA was $-8.555M, beating the average prediction of $-6.109M by 40.05%. Cidara Therapeutics's net income was $-8.172M, missing the average estimation of $-19.59M by -58.29%. The company's SG&A was $3.56M, missing the average forecast of $4.96M by -28.29%. Lastly, the company's EPS was $-0.09, missing the average prediction of $-3 by -97.00%